Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07545590
PHASE1
A Study of Eltrekibart (LY3041658) in Healthy Participants
Sponsor: Eli Lilly and Company
View on ClinicalTrials.gov
Summary
The main purpose of this study is to evaluate how eltrekibart is absorbed by the body when it is given under the skin to healthy participants. The study will last about 17 weeks.
Official title: A Phase 1, Open-Label, Single Dose Study to Investigate the Relative Bioavailability, Safety, and Tolerability of Two Formulations of Eltrekibart in Healthy Participants
Key Details
Gender
All
Age Range
21 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2026-04-21
Completion Date
2026-08
Last Updated
2026-06-23
Healthy Volunteers
Yes
Conditions
Interventions
DRUG
LY3041658
Administered SC
DRUG
LY3041658
Administered IV
Locations (1)
Lilly Centre for Clinical Pharmacology
Singapore, Singapore